02 Jan 2017
Reply
EU CTD Dossiers Available // Looking for Marketing Partners in the EU for various products [ENA00142]
Inventia Healthcare, one of the leading drug delivery companies in India is searching for partners in Europe for the following products which are at various stages of development -
Approved MA:
1. Duloxetine DR Capsules 30 mg/ 60 mg
Products Under development:
1. Gliclazide MR Tablets 30 mg/ 60 mg - EU fillable dossier will be ready by Oct 2017
2. Ezetimibe 10 mg Tablets - EU fillable dossier will be ready by Dec 2017
Products developed against international innovators and easily extendable to EU
1. Metformin SR Tablets 500 mg
2. Metformin SR Tablets 750 mg
3. Metformin SR Tablets 1000 mg
4. Darifenacin ER tablets 7.5 mg/ 15 mg
New Products Under development for EU
1. Rivaroxaban Tablets 10mg, 15 mg, 20 mg: will be ready by Q3 2019
2. Sitagliptin + Metformin: Target to be ready by Q2 2022
3. Mesalamine 1200 Gm Tablets - Target to be ready by Q3 2019
Interested partners should contact Priyanka Dhanjal at priyanka.dhanjal@inventiahealthcare.com or call +919987152274
Approved MA:
1. Duloxetine DR Capsules 30 mg/ 60 mg
Products Under development:
1. Gliclazide MR Tablets 30 mg/ 60 mg - EU fillable dossier will be ready by Oct 2017
2. Ezetimibe 10 mg Tablets - EU fillable dossier will be ready by Dec 2017
Products developed against international innovators and easily extendable to EU
1. Metformin SR Tablets 500 mg
2. Metformin SR Tablets 750 mg
3. Metformin SR Tablets 1000 mg
4. Darifenacin ER tablets 7.5 mg/ 15 mg
New Products Under development for EU
1. Rivaroxaban Tablets 10mg, 15 mg, 20 mg: will be ready by Q3 2019
2. Sitagliptin + Metformin: Target to be ready by Q2 2022
3. Mesalamine 1200 Gm Tablets - Target to be ready by Q3 2019
Interested partners should contact Priyanka Dhanjal at priyanka.dhanjal@inventiahealthcare.com or call +919987152274
tamar.javashvili@rational.ge
Rivaroxaban API needed in Georgia for leading pharmaceutical holding AVERSI (aversi.ge)
23:06, 17 Jul 2019
